文献速递炎症性肠病

替吉奥嘌呤在274例不耐受常规治疗的炎症性肠病患者队列中的持续有效性、安全性及治疗药物监测

Sustained effectiveness, safety and therapeutic drug monitoring of tioguanine in a cohort of 274 IBD patients intolerant for conventional therapies.
PubMed 文献 · Aliment Pharmacol Ther · 2019-05-16

这项全国性多中心回顾性研究纳入274例不耐受常规免疫调节治疗的炎症性肠病患者,中位替吉奥嘌呤疗程51个月、随访1567患者年。6个月临床有效率为66%,12个月持续有效率为51%,79%患者可耐受;41%发生不良事件、5%为重度。6-硫鸟嘌呤核苷酸阈值浓度>682 pmol/8×10^8红细胞与临床有效性相关。

要点

  • 替吉奥嘌呤长期维持治疗12个月持续有效率为51%,约70%患者可耐受。
  • 41%患者发生不良事件,5%为重度;8例皮肤癌(含2例黑色素瘤),3例感染需住院。
  • 6-硫鸟嘌呤核苷酸阈值浓度>682 pmol/8×10^8红细胞与临床有效性相关。

核心结论

  • 至少12个月的长期替吉奥嘌呤治疗对51%的炎症性肠病患者有效,约70%患者作为维持治疗耐受良好。
  • 不良事件常见,但主要为轻至中度;作者提出6-硫鸟嘌呤核苷酸目标水平≥700 pmol/8×10^8红细胞与更高的临床有效性 odds 相关。

研究设计与样本

  • 全国性、多中心研究,回顾性审查使用替吉奥嘌呤的炎症性肠病患者病历。
  • 共纳入274例患者(女性63%,克罗恩病68%),中位治疗时长51个月,随访1567患者年,替吉奥嘌呤中位剂量20 mg/d。

主要发现

  • 79%患者对替吉奥嘌呤耐受,66%患者在6个月时记录到临床有效性,51%患者在12个月内维持持续临床有效性。
  • 41%患者发生不良事件,其中5%为重度;不良事件包括3例需住院的感染和8例皮肤癌(其中2例黑色素瘤)。
  • 52例接受肝活检的患者中2例(3.8%)发生无症状结节性再生性增生,3例发生门静脉高压,其中1例可能与替吉奥嘌呤相关(0.4%)。
  • 临床有效性与6-硫鸟嘌呤核苷酸阈值浓度>682 pmol/8×10^8红细胞相关(P < 0.05)。

关键数值与推荐

  • 临床有效性定义为无(重新)启动糖皮质激素、合并生物制剂治疗或手术干预的临床有效。
  • 所有随访期间发生的不良事件按常见术语标准(CTC)列出并分级。
  • 6-硫鸟嘌呤核苷酸阈值浓度>682 pmol/8×10^8红细胞与临床有效性相关(P < 0.05)。
  • 作者提出6-硫鸟嘌呤核苷酸目标水平≥700 pmol/8×10^8红细胞与更高的临床有效性 odds 相关。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Tioguanine (or thioguanine) is an alternative drug for IBD patients who fail prior conventional immunomodulating therapy. AIM: To report effectiveness, safety and therapeutic drug monitoring in a cohort of patients with prolonged tioguanine maintenance therapy. METHODS: In this nationwide, multicentre study, medical records of tioguanine- using IBD patients were retrospectively reviewed. Response to therapy was defined as clinical effectiveness without (re)initiation of corticosteroids, concurrent biological therapy or surgical intervention. All adverse events that occurred during the follow-up were listed and graded according to the common terminology criteria (CTC). RESULTS: Two hundred and seventy-four patients (female 63%, Crohn's disease in 68%) were included with median treatment duration of 51 months, 1567 patient-years of follow-up and median 20 mg/d tioguanine dosage. Tioguanine was tolerated in 79%, clinical effectiveness at 6 months was documented in 66% and sustained clinical effectiveness during 12 months in 51% of patients. Forty-one per cent of patients developed adverse events: 5% were graded as severe. Adverse events comprised infection requiring hospitalisation in three and skin cancer in eight patients (two melanomas). Asymptomatic nodular regenerative hyperplasia of the liver occurred in two out of 52 patients with liver biopsies (3.8%) and portal hypertension in three whereof one potentially associated with tioguanine (0.4%). Clinical effectiveness was correlated with 6-thioguanine nucleotide threshold concentrations >682 pmol/8×108 RBC (P < 0.05). CONCLUSIONS: Long-term tioguanine therapy for at least 12 months was effective in 51% and well tolerated as a maintenance treatment for IBD in about 70% of patients. Adverse events were common, but mainly mild or moderate. 6-Thioguanine nucleotide threshold concentration ≥ 700 pmol/8×108 RBC is proposed as target level with higher odds for clinical effectiveness.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Simsek M, Deben DS, Horjus CS, et al. Sustained effectiveness, safety and therapeutic drug monitoring of tioguanine in a cohort of 274 IBD patients intolerant for conventional therapies. Aliment Pharmacol Ther. 2019. PMID: 31094013. doi:10.1111/apt.15280

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。